Sienna Biopharmaceuticals Announces SNA-120 (0.05%) Biopsy Data Demonstrate Positive Impact on Key Inflammatory Cytokines, including IL-23 and IL-17, in Psoriasis

Stock Information for Sienna Biopharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.